Neurath M (2014)
Publication Type: Journal article
Publication year: 2014
Publisher: Nature Publishing Group: Open Access Hybrid Model Option A
Book Volume: 7
Pages Range: 6-19
Journal Issue: 1
DOI: 10.1038/mi.2013.73
Healing of the inflamed mucosa (mucosal healing) is an emerging new goal for therapy and predicts clinical remission and resection-free survival in inflammatory bowel diseases (IBDs). The era of antitumor necrosis factor (TNF) antibody therapy was a remarkable progress in IBD therapy and anti-TNF agents led to mucosal healing in a subgroup of IBD patients; however, many patients do not respond to anti-TNF treatment highlighting the relevance of finding new targets for therapy of IBD. In particular, current studies are addressing the role of other anticytokine agents including antibodies against interleukin (IL)-6R, IL-13, and IL-12/IL-23 as well as new anti-inflammatory concepts (regulatory T cell therapy, Smad7 antisense, Jak inhibition, Toll-like receptor 9 stimulation, worm eggs). In addition, blockade of T-cell homing via the integrins ?4?7 and the addressin mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) emerges as a promising new approach for IBD therapy. Here, new approaches for achieving mucosal healing are discussed as well as their implications for future therapy of IBD.
APA:
Neurath, M. (2014). New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunology, 7(1), 6-19. https://doi.org/10.1038/mi.2013.73
MLA:
Neurath, Markus. "New targets for mucosal healing and therapy in inflammatory bowel diseases." Mucosal Immunology 7.1 (2014): 6-19.
BibTeX: Download